[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-low-back-pain-clbp\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-low-back-pain-clbp":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,47,0,25,[9,48,78,109,135,166,198,223,251,275,302,338,366,395,425,449,475,502,530,560,584,608,629,657,697],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100053918","impairment-based-treatment-versus-modified-functional-restoration-program-in-chronic-low-back-pain-patients-100053918",false,"NCT07699419","Impairment Based Treatment Versus Modified Functional Restoration Program in Chronic Low Back Pain Patients","FIRM-CLBP: a Randomized Controlled Feasibility Trial Comparing Impairment-based Treatment With a Modified Functional Restoration Program in Older Adults With Chronic Low Back Pain","FIRM-CLBP","Inclusion Criteria:\n\n* ≥ 60 years\n* Chronic Non-Specific Low Back Pain (CNSLBP)\n* Pain duration ≥ 12 weeks\n* No identifiable specific spinal pathology\n* Pain Location\n* Pain localized between the 12th rib and gluteal folds\n* With or without non-dermatomal referred pain not extending below the knee\n* Pain Intensity\n* Mean pain intensity ≥ 4\u002F10 on the Numeric Rating Scale (NRS) over the past 7 days\n* Functional Disability\n* Oswestry Disability Index (ODI) ≥ 20% (moderate disability or higher)\n* Mechanical Pain Characteristics\n* Presence of ≥ 2 of the following:\n* Pain aggravated by movement, loading, or prolonged postures\n* Pain relieved by rest or positional change\n* Morning stiffness \\\u003C 30 minutes\n* Absence of constant, non-mechanical night pain Functional Capacity\n* Able to ambulate independently (with or without assistive device)\n* Able to actively participate in an exercise-based rehabilitation program\n* Clinical Stability\n* Stable medication regimen (analgesics, anti-inflammatories, or related drugs) for ≥ 4 weeks\n* No planned changes in pharmacological treatment during the study period\n* Cognitive \\& Communication Ability\n* Able to understand study procedures and follow instructions\n* MMSE ≥ 24 (or equivalent cognitive screening)\n* Consent\n* Provides written informed consent\n\nExclusion Criteria:\n\n* 1\\. Specific Spinal Pathology (\"Red Flags\")\n\n  * Suspected or confirmed:\n  * Spinal fracture\n  * Malignancy\n  * Spinal infection\n  * Inflammatory spondyloarthropathy\n\nClinical indicators:\n\nUnexplained weight loss Fever or systemic illness History of significant trauma\n\n2\\. Radicular or Neurological Involvement\n\n* Radiculopathy defined by ANY of:\n* Dermatomal pain radiating below the knee\n* Progressive motor weakness\n* Objective neurological deficit (sensory, reflex, or motor)\n\n  3\\. Lumbar Spinal Stenosis (Severe)\n* Neurogenic claudication limiting walking to \\\u003C 100 meters, OR\n* Symptoms not relieved by rest or flexion\n\n  4\\. Prior Surgical or Structural Conditions Lumbar spine surgery within the past 12 months\n\n  5\\. Medical Contraindications to Exercise\n* Severe osteoporosis with high fracture risk\n* Uncontrolled cardiovascular, respiratory, or metabolic disease\n* Any condition precluding safe participation in rehabilitation\n\n  6\\. Cognitive or Behavioral Barriers\n* Severe cognitive impairment (MMSE \\\u003C 24)\n* Inability to comply with study procedures\n\n  7\\. Confounding Treatment Factors\n* Participation in structured physiotherapy or rehabilitation within the past 3 months\n* Planned concurrent rehabilitation during the study\n\n  8\\. Psychosocial Confounders Ongoing litigation or compensation claims related to low back pain",true,"ALL","60 Years",{"count":22,"type":23},18,"ESTIMATED","INTERVENTIONAL",[26],"NA","The aim of this feasibility study is to evaluate the practicality of conducting a future randomized controlled trial comparing two rehabilitation approaches for older adults with degenerative chronic low back pain: impairment-based treatment (IBT) and a modified short Functional Restoration Program (FRP).\n\nImpairment-based treatment is an individualized approach in which interventions are tailored to the patient's specific physical deficits, such as limitations in mobility, strength, and motor control. In contrast, the Functional Restoration Program is a structured, standardized approach focusing on improving overall functional capacity through progressive exercise, movement retraining, and activity-based rehabilitation.\n\nParticipants will be randomly allocated to one of the two groups. Both interventions will be delivered by trained physiotherapists following standardized protocols over a 6-week period, with supervised sessions conducted according to a predefined rehabilitation schedule.",[29],"Chronic Low Back Pain (CLBP)",[31,32,33,34],"LBP","Old age","Impairment","Functional","NOT_YET_RECRUITING","2026-07-07",{"date":38,"type":39},"2026-07-13","ACTUAL",{"date":41,"type":23},"2026-07-01",{"date":43,"type":23},"2027-01-10",{"name":45,"class":46},"Cairo University","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":19,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":24,"phases":59,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":47},"100645128","comparing-strategies-to-improve-non-pharmacologic-pain-relief-for-adults-with-back-pain-using-the-education-navigated-care-and-supported-self-management-pain-care-program-100645128","NCT07679178","Comparing Strategies to Improve Non-Pharmacologic Pain Relief for Adults With Back Pain Using the Education, Navigated Care, and Supported Self-management Pain Care Program","Comparing Strategies to Improve Non-Pharmacologic Pain Relief for Adults With Back Pain (The ENCompaSS Trial)","ENCompaSS","Inclusion Criteria:\n\n* Be age 18 years old or older\n* Have a VA outpatient clinic visit for low back pain within the previous 30 days\n* Be enrolled in a participating primary care clinic\n* Have high impact chronic pain per Graded Chronic Pain Scale (most days or every day on first 2 items)\n* Valid telephone access\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Are currently hospitalized or residing in a nursing home\n* Have cognitive impairment or lack of decision-making capacity\n* Have a serious mental illness (e.g., schizophrenia, bipolar disorder, recent psychiatric hospitalization, high risk suicide flag)\n* Are unable to communicate by telephone or have no telephone access","18 Years",{"count":58,"type":23},530,[26],"The goal of this clinical trial is to help Veterans manage high-impact chronic low back pain. The trial will use a program, ENCompaSS (Education, Navigated Care, and Supported Self-Management) designed to reduce pain more than usual care alone. Researchers will assess a) the impact of ENCompaSS, b) identify which Veterans benefit the most, and c) how this program can be delivered more broadly in other clinics and health systems.\n\nWhat Will Happen:\n\nVeterans in this clinical trial will be randomly placed into one of two groups.\n\nENCompaSS group (intervention):\n\n* Have at least three phone calls with a trained clinician over about 12 weeks\n* Watch short online videos about managing pain\n* Complete surveys before the study and again at 2, 4, 6, and 12 months\n\nUsual care group:\n\n* Will continue with regular care\n* Complete the same surveys at the same time points",[62,63],"Chronic Low-back Pain (cLBP)","High-Impact Chronic Pain (HICP)",[65,66,67,68,69],"Veterans","Low Back Pain","Clinical Pathway","Pain Management","Non-Pharmacologic","2026-06-25",{"date":41,"type":39},{"date":73,"type":23},"2026-10",{"date":75,"type":23},"2029-07-31",{"name":77,"class":46},"Duke University",{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":19,"minAge":56,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":24,"phases":88,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":47},"100630937","imaging-metabolic-and-perfusion-changes-in-acupuncture-therapy-for-myofascial-pain-syndrome-100630937","NCT07494162","Imaging Metabolic and Perfusion Changes in Acupuncture Therapy for Myofascial Pain Syndrome","IMPACT-MPS: Imaging Metabolic and Perfusion Changes in Acupuncture Therapy for Myofascial Pain Syndrome","IMPACT-MPS","Inclusion Criteria:\n\n* Ability to understand the purposes and risks of the trial and willingness to sign an informed consent form\n* Willingness and ability to comply with all protocol required procedures\n* Willingness to be randomized to receive either true acupuncture or sham acupuncture\n* Current self-report of chronic low back pain (cLBP) which has persisted for the past 3 months AND has resulted in pain on \\> 50% of days in the past 6 months\n* At least one palpable nodule or taut band in paraspinal, quadratus lumborum, or gluteal muscles\n* Reproduction of the patient's dominant pain with palpation of a muscle nodule or taut band\n* Predominantly paramedian pain (may be uni-lateral or bi-lateral)\n* Willing and able to lay motionless in a supine position at least twice, preferably thrice: 70-minute TB-PET\u002FCT scan\n* Willing and able to fast for at least 6 hours before and for the duration of the TB-PET\u002FCT scan\n* Willing to avoid strenuous exercise for 24 hours before the TB-PET\u002FCT scan visit\n* Willingness to practice effective contraception during the study.\n\nExclusion Criteria:\n\n* No Primary Care Physician\n* History of spine infection (discitis or osteomyelitis) or spine tumor\n* History of ankylosing spondylitis, rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, or lupus\n* Confounding conditions that are known to be responsible for inducing pain\n* Implants at or in the region of the sites of interest\n* Diagnosis of any vertebral fracture in the last 6 months\n* Cauda equina syndrome or lumbar radiculopathy with functional motor deficit (strength\\\u003C4\u002F5 on manual motor testing)\n* Spinal implants (including fixation hardware, spinal cord stimulator, intra-thecal pumps, that are present in the region of the sites of interest)\n* Predominantly central pain\n* Pain below the knee\n* Positive straight leg raise test\n* Symptomatic hip arthritis\n* Uncontrolled claustrophobia\n* Pregnant or lactating participants\n* Body weight more than 225 kg (496 pounds) due to the weight limitation of the scanner bed\n* Prisoners\n* Inability to speak, read, and write in the English language\n* Concurrent or prior enrollment in a separate research study involving a PET scan performed within the last 12 months for research purposes only.\n\nThat is, PET scans are not performed as part of a patient's treatment plan (e.g. standard of care, therapeutic purposes, or clinical care) and the research study did not intend to provide therapeutic benefit to the patient.\n\n•Any other criteria, which would make the participant unsuitable to participate in this study as determined by the Principal Investigator",{"count":87,"type":23},64,[26],"This study will evaluate the clinical and biological effects of acupuncture for chronic low back pain associated with myofascial pain syndrome (MPS).\n\nIn this randomized, participant- and assessor-blinded clinical trial, 64 adults with chronic low back pain due to MPS will be assigned to receive either true acupuncture or sham acupuncture for eight weeks. Participants will undergo total-body positron emission tomography\u002Fcomputed tomography (TB-PET\u002FCT) imaging and complete standardized pain and functional questionnaires at baseline and after treatment.\n\nThe study will evaluate whether acupuncture improves pain and function compared with sham treatment and whether TB-PET\u002FCT imaging can detect changes in myofascial tissue metabolism and perfusion that correspond with clinical outcomes.",[91,62],"Myofascial Pain Syndrome (MPS)",[93,94,95,96,97,98],"acupuncture treatment","Total-Body PET","FDG PET","Myofascial Pain Syndrome","Chronic Low Back Pain","Imaging Biomarkers","RECRUITING","2026-06-15",{"date":102,"type":39},"2026-06-17",{"date":104,"type":39},"2026-05-18",{"date":106,"type":23},"2030-04",{"name":108,"class":46},"University of California, Davis",{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":12,"sex":19,"minAge":56,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":24,"phases":120,"briefSummary":121,"conditions":122,"keywords":123,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":131,"leadSponsor":133,"locationsCount":47},"100642277","focal-extracorporeal-shock-wave-therapy-with-two-different-dosing-regimens-for-chronic-low-back-pain-100642277","NCT07646132","Focal Extracorporeal Shock Wave Therapy With Two Different Dosing Regimens for Chronic Low Back Pain","Effects of Two Dosing Regimens of Focal Extracorporeal Shock Wave Therapy in Patients With Chronic Low Back Pain: A Randomized Clinical Trial","ESWT-LBP","Inclusion Criteria:\n\n* Individuals of both sexes.\n* Age between 18 and 65 years.\n* Clinical diagnosis of mechanical chronic low back pain (cLBP), defined as pain localized between the lower costal margin and the gluteal fold, with at least 12 weeks of evolution.\n* Lumbar pain intensity of at least 5\u002F10 on the Numeric Pain Rating Scale (NPRS).\n* Predominantly mechanical pain, exacerbated by activities such as prolonged standing, trunk movements, extension, or lumbar rotation, and without clinical data of predominant radicular pain.\n* Plain radiograph of the lumbar spine available as part of the baseline evaluation.\n* Ability to attend all 4 treatment sessions and subsequent follow-up evaluations.\n* Signed informed consent form previously approved by the Institutional Review Board \u002F Research Ethics Committee.\n\nExclusion Criteria:\n\n* Low back pain of probable non-mechanical origin or secondary to a specific cause that substantially modifies clinical management.\n* Clinical data of predominant lumbar radiculopathy, including pain radiating below the knee with a dermatomal distribution, focal motor deficit, objective sensory alterations, or compatible reflex changes.\n* Diagnosis or suspicion of cauda equina syndrome.\n* History of previous lumbar spine surgery.\n* Current vertebral fracture or recent history of lumbar fracture.\n* Spondylolisthesis grade II or higher.\n* Significant structural scoliosis or severe lumbar deformity that prevents treatment standardization.\n* Suspicion or evidence of a tumor, infection, spondylodiscitis, or axial inflammatory disease.\n* Severe clinically documented osteoporosis or history of vertebral fragility fracture.\n* Pregnancy or lactation.\n* Coagulation disorder, use of anticoagulants at therapeutic doses, or a hemorrhagic condition that increases procedure risk.\n* Previous epidural infiltration, facet block, radiofrequency, or other lumbar interventional procedure within a recent period defined by the protocol.\n* Current treatment with another physical rehabilitation modality or instrumental therapy directed at low back pain, if it cannot be suspended during the intervention period.\n* Current use of nonsteroidal anti-inflammatory drugs (NSAIDs) that the patient cannot suspend according to the study indications.\n* Concomitant neurological, rheumatological, oncological, or musculoskeletal disease that significantly interferes with pain or disability evaluation.\n* Cognitive impairment, decompensated psychiatric disorder, or any condition that prevents understanding instructions, answering questionnaires, or completing follow-up.","80 Years",{"count":119,"type":23},60,[26],"The purpose of this clinical trial is to evaluate and compare the efficacy of two different dosing regimens of focal extracorporeal shock wave therapy (F-ESWT) in patients diagnosed with chronic mechanical low back pain. Participants will be randomly assigned to one of two experimental groups to receive different parameters of shock wave intervention. The main objective is to determine which dosing scheme provides a more significant reduction in pain intensity and a better recovery of lumbar function.",[29],[124,66,125,126],"Focal Extracorporeal Shock Wave Therapy","Dosing Regimens","Physical Medicine and Rehabilitation","2026-06-09",{"date":129,"type":39},"2026-06-12",{"date":100,"type":23},{"date":132,"type":23},"2028-01-30",{"name":134,"class":46},"Armando Tonatiuh Avila Garcia",{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":19,"minAge":143,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":24,"phases":147,"briefSummary":148,"conditions":149,"keywords":150,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":47},"100640141","seneca---smart-therapies-for-chronic-pain-100640141","NCT07628179","SENECA - Smart Therapies for Chronic Pain","Efficacy of Percutaneous Auricular Vagus Nerve Stimulation Within the Multimodal Pain Therapy (SENECA): A Randomized Controlled Pilot Study","SENECA","Inclusion Criteria:\n\n* Male or female aged between 30 and 65 years\n* Indication: chronic myofascial\u002Fmusculoskeletal back pain\n* normal function of spinal nerves\n* Intractable pain for more than 6 months\n* Patient on oral pharmacotherapy ≤ WHO II with no adequate response or intolerant\n* Average pain over the last 4 weeks according to the painDETECT subscale ≥ 4 and ≤ 9 at baseline\n* ODI 20-80 at baseline\n* Basic digital understanding to work with the patient pain app\n* Patient understands the therapy and procedures, agrees to its provisions, and gives written informed consent prior to any procedures\n\nExclusion Criteria:\n\n* Organic low back pain (trauma, fracture, tumor, infection, severe degenerative spine, documented high-grade spinal stenosis, rheumatologic conditions)\n* Indication for back surgery\n* Back surgery within the last 6 months\n* New analgesics 2 weeks before baseline (paracetamol, NSAIDs, Metamizol, etc.)\n* Opioid analgesic therapy \\> WHO II\n* New physical therapy modalities for back pain, also TENS, 2 weeks before baseline\n* History of vagus nerve stimulation or electrical auricular stimulation\n* History of vasovagal syncope\n* High BMI \\> 35 kg\u002Fm² (Obesity Class 2 or higher)\n* Hemophilia\n* Autonomic disorders\n* Advanced stage or poorly controlled diabetes mellitus type I or II\n* Poorly controlled high blood pressure\n* Major psychiatric comorbidity (HADS \\> 10 on each subscale at baseline)\n* Other serious clinically relevant co-morbidity\n* History of arrhythmia, bradycardia, other rhythm disorders or any other clinically significant cardiac anomalies\n* Infection, eczema, or psoriasis at application site (ear and neck)\n* Numbed and desensitized skin at the application site (ear and neck)\n* Chronic drug or alcohol abuse within the last 6 months\n* Pregnant or nursing female patients\n* Active implantable device\n* Open pension request\n* Currently participating in another clinical trial or participated over the last 3 months\n* Change in concomitant treatment or medication during the study","30 Years","65 Years",{"count":146,"type":23},44,[26],"This will be a randomized controlled prospective pilot study: The feasibility and usability of VIVO 2nd GEN therapy + Standard-of-Care (SoC) vs. Standard-of-Care alone will be evaluated.\n\nAt baseline, after informed consent and evaluation of inclusion and exclusion criteria, evaluation of pain on painDETECT, quality of life (EQ-5D-5L questionnaire), mental health (HADS questionnaire), and the effect of back pain on function and daily activities (ODI questionnaire) will be performed. After that, all patients will start their multimodal treatment plan.\n\nThe control group will only receive SoC multimodal therapy training (this includes specifically: physio group therapy, water therapy, strength training, Nordic walking, massages, thermos therapy, lectures and trainings, psychotherapy, local electrotherapy).\n\nThe treatment group will additionally receive pVNS as add-on therapy. Within this study the next generation device VIVO 2nd GEN will be used within a pVNS proofed indication.\n\nThe study documentation in both groups will be supported by a digital diary App (VIVO® Pal) and an online dashboard for physicians\u002Ftherapists (Therapy Management System - TMS), allowing for pseudonymized data entries and management.\n\nPatients will remain on treatment for 4 weeks. All patients will be evaluated using questionnaires (painDETECT, EQ-5D-5L, HADS, ODI) at baseline, weekly during treatment for 4 weeks, by end of treatment and at 4 weeks (optional 3 months and 6 months) follow-up (e.g., via telephone or the App, see below).",[29],[151,152,153,154,155],"auricular vagus nerve stimulation","chronic pain","neuromodulation","multimodal pain therapy","digital therapy management","2026-06-03",{"date":158,"type":39},"2026-06-04",{"date":160,"type":23},"2026-09-17",{"date":162,"type":23},"2027-04-30",{"name":164,"class":165},"Aurimod GmbH","INDUSTRY",{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":18,"sex":19,"minAge":172,"maxAge":144,"enrollmentInfo":173,"targetDuration":4,"studyType":24,"phases":175,"briefSummary":177,"conditions":178,"keywords":185,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":47},"100437952","early-phase-1-brain-mechanisms-supporting-cannabis-induced-pain-relief-100437952","NCT04982965","Brain Mechanisms Supporting Cannabis-induced Pain Relief","Inclusion Criteria:\n\n* Between 21-65 years old\n* Currently 30 days cannabis free\n* Lower back pain for three months or more\n* Are not taking opioids\n* If female and of a child bearing potential age, are not pregnant or nursing mothers\n* Do not have mental or neurological conditions inhibiting sensory\u002Fmotor functions\n* Do not have a lifetime history of dependence on cannabis\n* Do not have a lifetime history of DSM-IV schizophrenia, bipolar disorder, panic disorder, or psychosis\n* Prior THC-containing cannabis experience within the past two years\n* Agrees not to use cannabis outside of the study during participation in the study\n* Agrees not to use opioids or barbiturates during participation in the study\n* Agrees not to drive a motor vehicle within 4 hours following last use of inhaled cannabis during participation in the study\n\nExclusion Criteria:\n\n* Active pulmonary disease\n* Allergy or past adverse effects or negative past experiences from cannabis\n* Positive urine drug test for THC, barbiturates, opioids, oxycodone, or methadone\n* Any significant illness, including cardiovascular disease, diabetes, renal and liver disease.\n* Any current or history of an immunocompromising disease or condition (such as lupus, psoriasis, multiple sclerosis, etc.)\n* Any current or history of neurologic conditions, including Parkinson disease, dementia, cognitive impairment, history of seizure disorder, and history of traumatic brain injury\u002Fhead injury\n* Any current major psychiatric illness, such as bipolar disorder, major depression, psychosis, substance use disorder, or schizophrenia\n* Any current or history of suicidal ideation or attempt\n* Overt sensitivity to thermal stimulation\n* Resting blood pressure \\> 140\u002F90\n* Resting heart rate \\> 100 beats\u002Fminute\n* Prisoner\n* Institutionalized\n* Claustrophobia\n* MRI contraindications\n* Participation in any new (within 2 weeks prior or any time after enrollment) pain management procedures during the study period\n* Known history of vasovagal fainting, syncope, or severe adverse reactions associated with blood draws or needle procedures","21 Years",{"count":174,"type":23},100,[176],"EARLY_PHASE1","Chronic low back pain is a common and disabling condition that affects millions of people in the United States. Many people with chronic low back pain do not get enough relief from current treatments. Cannabis may help reduce pain, but researchers do not fully understand how it affects the brain in people with chronic pain. The purpose of this study is to examine how inhaled cannabis changes brain activity and reduces pain in people with chronic low back pain. Results from this study may help researchers better understand how cannabis works for pain and support the development of improved pain treatments.",[179,180,181,182,62,183,184],"Sciatica","Lumbar Radiculopathy","Lower Back Pain","Degenerative Disc Disease","Chronic Low Back and Leg Pain","Back Pain",[186,187,188,189],"Cannabis","Vaporized cannabis","THC","chronic low back pain","2026-05-30",{"date":156,"type":39},{"date":193,"type":39},"2021-05-07",{"date":195,"type":23},"2027-03-15",{"name":197,"class":46},"University of California, San Diego",{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":12,"sex":19,"minAge":56,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":24,"phases":207,"briefSummary":208,"conditions":209,"keywords":210,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":47},"100605372","chronic-low-back-pain-and-osteopathic-manipulation-treatment-100605372","NCT07161661","Chronic Low Back Pain and Osteopathic Manipulation Treatment","Feasibility of Implementing Manual Medicine in the Multimodal Management of Veterans and Service Members With Chronic Low Back Pain","Inclusion Criteria:\n\n* 18 years of age and older\n* Seeking care for LBP from a participating VA clinic\n* Able to follow study protocol\n* Willing to be randomized to Usual VA Care or Usual VA Care + OMT\n* Individuals with pain primarily in the LBP region lasting \\> 3 months and present on at least half the days during the past 6 months\n* Pain rating over the past 7 days equal to or greater than 3\u002F10 as indicated on the Numeric Rating Scale for Pain\n\nExclusion Criteria:\n\n* Signs of serious pathology as a cause of LBP\n* Underlying systemic or inflammatory conditions\n* Neurological diseases\n* Pregnancy\n* Previous back surgery or spinal fracture within the past year\n* Active workers' compensation or litigation for back pain\n* Any conditions impeding study protocol implementation or contraindication to OMT\n* No PM\\&R, OMT, chiropractic, or physical treatment where manual techniques are utilized within last 3mo",{"count":206,"type":23},48,[26],"The goal of this clinical trial is to learn if adding Osteopathic Manipulative Therapy (OMT) to the usual medical care provided at the VA (usual VA care) improves treatment outcomes in individuals with chronic low back pain (CLBP). OMT is a set of hands-on techniques a doctor uses to move a patient's muscles and joints which include stretching, gentle pressure, resistance and applying forces to specific areas of the body. This feasibility clinical trial aims to learn about the treatment effects (e.g., effect sizes) of adding OMT to the usual medical care provided at the VA (Usual VA Care) in individuals with LBP.",[29,66],[211,126,65,212],"Osteopathic manipulative treatment","Osteopathic manipulation","2026-05-21",{"date":215,"type":39},"2026-05-22",{"date":217,"type":39},"2026-03-02",{"date":219,"type":23},"2027-08-31",{"name":221,"class":222},"Edward Hines Jr. VA Hospital","FED",{"id":224,"slug":225,"hasResults":12,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":12,"sex":19,"minAge":56,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":24,"phases":233,"briefSummary":235,"conditions":236,"keywords":239,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":250},"100595641","phase-3-a-study-of-retatrutide-ly3437943-in-participants-who-have-obesity-or-overweight-and-chronic-low-back-pain-100595641","NCT07035093","A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain","TRIUMPH-7","Inclusion Criteria:\n\n* Have a history of axial-predominant low back pain\n* Have pain that is restricted to the low back or with a referral pattern limited to the proximal legs\n* Have a body mass index (BMI) ≥27 kilograms per square meter (kg\u002Fm2) at screening\n* Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight\n\nExclusion Criteria:\n\n* Have a non-axial origin low back pain\n* Have had botulinum or steroid injections to the spine within 1 year of screening\n* Have had trigger point injection to the spine within 6 months of screening\n* Have a self-reported change in body weight \\>5 kilograms (kg) (11 pounds) within 90 days prior to screening\n* Have been taking drugs to promote body weight reduction, including over-the-counter medications, within 90 days prior to screening\n* Have a prior or planned surgical treatment for obesity\n* Have Type 1 Diabetes, Type 2 Diabetes, or any other type of diabetes",{"count":232,"type":23},586,[234],"PHASE3","The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.",[237,238,29],"Obesity","Overweight",[240],"Axial Predominant Low Back Pain","2026-05-19",{"date":243,"type":39},"2026-05-20",{"date":245,"type":39},"2025-05-29",{"date":247,"type":23},"2027-09",{"name":249,"class":165},"Eli Lilly and Company",40,{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":12,"sex":19,"minAge":56,"maxAge":144,"enrollmentInfo":258,"targetDuration":4,"studyType":24,"phases":260,"briefSummary":261,"conditions":262,"keywords":263,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":47},"100607796","how-osteopathic-treatment-affects-the-leg-and-foot-in-people-with-low-back-pain-100607796","NCT07193212","How Osteopathic Treatment Affects the Leg and Foot in People With Low Back Pain","Osteopathic Manipulation Treatment Effect on the Leg and Foot Myofascial System in Adults With Chronic Low Back Pain - Pilot Study","Inclusion Criteria:\n\n* male and female subjects 18-65 years old\n* presence of chronic low back \\> 3 months duration or pain present \\> 50% of the time within the previous 12 months\n\nExclusion Criteria:\n\n* prior surgery of the thoracic, lumbar or sacral spine, pelvis\n* diagnosis lumbar radiculopathy or pinched nerve in the neck\n* diagnosis of foot condition that alters gait\n* diagnosis of connective tissue or muscle disorders\n* diagnosis of cancer\n* previous spinal cord injury inflammatory arthritis and fibromyalgia\n* pregnancy\n* tobacco use\n* known diabetes or prediabetes\n* allergy to ultrasound gel (propylene glycol)\n* history of manual therapy treatment within the past 2 weeks\n* injection for pain within the past 1 month\n* currently taking muscle relaxers",{"count":259,"type":23},20,[26],"This pilot study will examine whether osteopathic manipulative treatment (OMT) can improve both physical and psychological aspects of chronic low back pain by focusing on the interconnected myofascial system of the back, legs, and feet. Twenty adults with chronic low back pain will receive four OMT sessions over 5-7 weeks. Before and after treatment, the investigators will measure muscle stiffness with ultrasound, plantar pressure during walking with a pressure plate, and patient-reported outcomes on pain, disability, sleep quality, stress, anxiety, depression, pain catastrophizing, and pain self-efficacy using surveys. By linking these objective and subjective measures, the study aims to provide early evidence of how OMT may influence musculoskeletal function, daily activity, and overall well-being, helping to guide future larger studies on treatment strategies for low back pain",[29],[189,264,265],"myofascial systems","omt","2026-05-12",{"date":268,"type":39},"2026-05-14",{"date":270,"type":39},"2025-11-05",{"date":272,"type":23},"2026-12",{"name":274,"class":46},"Edward Via Virginia College of Osteopathic Medicine",{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":12,"sex":19,"minAge":56,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":24,"phases":284,"briefSummary":285,"conditions":286,"keywords":290,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":47},"100532108","brief-pain-exposure-therapy-bpet-for-nociplastic-pain-100532108","NCT06208514","Brief Pain Exposure Therapy (BPET) For Nociplastic Pain","BPET","Inclusion Criteria:\n\n* Able to read, write and speak English\n* Internet access and audio-visual conferencing capability (e.g., Zoom meetings by phone or computer) in the home\n\nFibromyalgia participants must have:\n\n* Physician diagnosis of fibromyalgia\n* OR: meet 2016 American College of Rheumatology (ACR) Criteria for FM: Widespread pain index score is ≥ 7 and symptom severity scale score is ≥ 5, or widespread pain index score is 4 to 6 and symptom severity score is ≥ 9\n* OR: have pain self-reported in 4 out of 7 body regions in the General Sensory Sensitivity (GSS)-brief body map AND Opioid Use Disorder diagnosis by a physician.\n\nLupus participants must have:\n\n* Physician diagnosis of systemic lupus erythematosus\n* AND: Have pain self-reported in 4 out of 7 body regions in the GSS-brief body map\n* AND: No change in medications or steroid dose for one month prior to entry (to avoid oscillation of steroid dosing during the study due to active disease).\n\nChronic Low Back Pain participants must have:\n\n* Low Back Pain for at least half the days over the past 6 months\n* Over the past 7 days, an average pain intensity of at least 4 out of 10\n\nExclusion Criteria:\n\n* Indication of a co-occurring (non-fibromyalgia OR non-lupus) cause of chronic pain (e.g., inflammatory arthritis, other autoimmune disorders, spinal cord injury, cancer)\n* Currently receiving cognitive-behavioral therapy or other psychological therapies for pain\n* Open litigation regarding chronic pain in the past 1 year, as assessed in preliminary study screening.\n* Inability to provide informed consent and complete study procedures (e.g., indications of suspected major cognitive impairment via observations of study staff during consenting) that would preclude comprehension or participation in study protocols.\n* Pregnant or breastfeeding\n* Any other diseases or conditions that would make a patient unsuitable for study participation as determined by the site principal investigators.\n* Lupus group only: taking \\>10 mg prednisone (or equivalent steroid) dose per day as an indicator of ongoing disease activity (with no other strict exclusions based on medications)\n* Chronic Pelvic Pain group only: surgery for any chronic pelvic pain related condition in the past 6 months\n* Chronic low back pain only: scheduled back surgery; leg pain that is greater than your back pain",{"count":283,"type":23},125,[26],"This study is intended to test whether a brief Zoom-based behavioral treatment can help adults with fibromyalgia (FM), Lupus, chronic pelvic pain, and chronic low back pain learn effective strategies for reducing pain, disability and other problems that can come with fibromyalgia, Lupus, chronic pelvic pain, and chronic low back pain (such as depression or anxiety).",[287,288,289,29],"Fibromyalgia","Lupus Erythematosus, Systemic","Chronic Pelvic Pain",[291,292],"Pain exposure therapy","Telehealth-based behavioral intervention","2026-05-06",{"date":295,"type":39},"2026-05-11",{"date":297,"type":39},"2024-03-04",{"date":299,"type":23},"2027-07",{"name":301,"class":46},"University of Michigan",{"id":303,"slug":304,"hasResults":12,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":308,"eligibilityCriteria":309,"healthyVolunteers":12,"sex":19,"minAge":56,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":24,"phases":312,"briefSummary":313,"conditions":314,"keywords":323,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":47},"100622663","biologic-injection-for-adults-with-lumbar-disc-herniation-100622663","NCT07386548","Biologic Injection For Adults With Lumbar Disc Herniation","Bone Marrow Aspirate Concentrate Injection With MRI's - A Prospective Randomized Control Trial","BMAC","Inclusion Criteria:\n\n* Male or female patients ≥ 18 years of age\n* Clinically and\u002For radiographically (MRI) confirmed diagnosis of degenerative disc disease of the lumbar spine, lumbar disc herniation, and indication for lumbar microdiscectomy surgery\n* Unresponsive to conservative\u002Fnon-operative treatment for \\>3 months\n* Psychosocial, mental and physical ability to understand and to adhere to this protocol, especially adhering to the visit schedule follow-ups and observe the treatment plan\n\nExclusion Criteria:\n\n* Prisoners\n* Individuals who are not yet adults (infants, children, teenagers)\n* Individuals who are not able to clearly understand English\n* Adults with diminished capacity to consent\n* Major cognitive impairment causing to inability to understand and provide informed consent\n* Active malignancy\n* Active chronic or acute infection\n* Autoimmune disorder that impacts the lumbar spine (ankylosing spondylitis, lupus e.g.)\n* Bone marrow-derived or non-bone marrow-derived cancer\n* Low platelet count or clotting disorders\n* Prior surgery at the level to be treated or the adjacent level",{"count":311,"type":23},90,[26],"The goal of this clinical trial is to find out whether adding a bone-marrow aspirate concentrate (BMAC) injection during surgery can improve recovery in adults undergoing lumbar microdiscectomy for a lumbar disc herniation.\n\nThe main questions it aims to answer are:\n\n* Does the BMAC injection lead to better disc tissue health after surgery (as seen on MRI scans)?\n* Does the BMAC injection lead to greater improvement in pain and disability compared to surgery alone?\n\nParticipants will be adults aged 18 and older who are scheduled for lumbar microdiscectomy surgery.\n\nResearchers will compare one group of participants receiving the standard-of-care surgery plus the BMAC injection with another group receiving the same surgery without the injection to see if the injection offers added benefit.\n\nParticipants will:\n\n* Have surgery (microdiscectomy) with or without the injection.\n* Complete pain and disability questionnaires at several times over 2 years.\n* Undergo MRI scans at baseline and follow-up to assess disc structure and tissue health.\n* Provide samples of leftover disc or bone-marrow tissue (as applicable) from surgery for analysis.",[182,315,316,317,318,319,320,321,66,29,322],"DDD","Degenerative Disc Disease Lumbar","Degenerative Disc Disease, Lumbar","Lumbar Disc Herniation","Disc Herniation, Lumbar","Bone Marrow Aspirate Concentrate","Intervertebral Disc Displacement","CLBP - Chronic Low Back Pain",[324,325,326,327,328],"degenerative disc disease","lumbar disc herniation","bone marrow aspirate concentrate","intervertebral disc displacement","low back pain","2026-04-14",{"date":331,"type":39},"2026-04-16",{"date":333,"type":23},"2026-05-01",{"date":335,"type":23},"2030-12",{"name":337,"class":46},"Weill Medical College of Cornell University",{"id":339,"slug":340,"hasResults":12,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":12,"sex":19,"minAge":345,"maxAge":346,"enrollmentInfo":347,"targetDuration":4,"studyType":24,"phases":349,"briefSummary":350,"conditions":351,"keywords":353,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":47},"100633696","efficacy-of-electroacupuncture-combined-with-auricular-acupressure-for-chronic-low-back-pain-100633696","NCT07530042","Efficacy of Electroacupuncture Combined With Auricular Acupressure for Chronic Low Back Pain.","Efficacy of Electroacupuncture Combined With Auricular Acupressure in Patients With Chronic Low Back Pain Due to Lumbar Spondylosis With Kidney Yin Deficiency Syndrome: A Randomized Controlled Trial.","Inclusion Criteria:\n\n* Age between 40 and 70 years.\n* Low back pain persisting for ≥ 12 weeks.\n* Pain intensity: 30 ≤ VAS ≤ 70.\n* Disability index: ODI ≥ 10%.\n* Diagnosed with Lumbar Spondylosis by a physician, supported by clinical signs (mechanical pain) and imaging (X-ray or MRI showing degeneration).\n* Diagnosed with Kidney Yin deficiency syndrome by a certified TCM physician, exhibiting symptoms such as: lower back\u002Fknee soreness, afternoon fever\u002Fhot flashes, night sweats, tinnitus, dry mouth, red tongue, or rapid\u002Ffine pulse.\n* Voluntary consent to participate.\n\nExclusion Criteria:\n\n* Contraindications to auricular acupressure (e.g., ear skin infection) or electroacupuncture (e.g., pregnancy, severe heart failure, surgical indications, pacemakers, metal implants).\n* Specific causes of low back pain (e.g., infection, tumor, osteoporosis, ankylosing spondylitis, fracture).\n* Disc herniation with surgical indications (e.g., muscle atrophy, severe limb weakness, or sphincter dysfunction).\n* Currently participating in other interventional studies.\n* Currently taking medications that may affect study outcomes (painkillers, muscle relaxants, antidepressants, TCM drugs).","40 Years","70 Years",{"count":348,"type":23},76,[26],"Chronic low back pain (CLBP) due to lumbar spondylosis is a leading cause of disability, significantly impacting the quality of life in middle-aged and elderly populations. While electroacupuncture (EA) and auricular acupressure (AA) are recognized as safe, non-pharmacological therapies, high-quality clinical evidence specifically evaluating their combined effects on CLBP patients with TCM \"Kidney Yin deficiency\" syndrome remains limited.This randomized controlled trial aims to evaluate the efficacy and safety of combining EA with AA (utilizing Vaccaria segetalis seeds) compared to EA combined with sham AA. The study will focus on 76 eligible patients at Le Van Thinh Hospital. Primary objectives are to measure changes in pain intensity (VAS) and functional improvement (ODI) at three intervals: baseline (T0), after 7 days (T1), and upon completion of the 14-day intervention (T2). The findings are expected to provide an evidence-based foundation for an integrated treatment approach to manage chronic lumbar pain effectively.",[29,352],"Lumbar Spondylosis",[354,355,356],"Electroacupuncture","Auricular Acupressure","Kidney Yin Deficiency","2026-04-08",{"date":359,"type":39},"2026-04-15",{"date":361,"type":23},"2026-04-20",{"date":363,"type":23},"2026-12-31",{"name":365,"class":46},"University of Medicine and Pharmacy at Ho Chi Minh City",{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":372,"eligibilityCriteria":373,"healthyVolunteers":18,"sex":19,"minAge":56,"maxAge":374,"enrollmentInfo":375,"targetDuration":4,"studyType":24,"phases":377,"briefSummary":378,"conditions":379,"keywords":380,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":47},"100631188","neuroimmune-responses-to-exercise-in-chronic-back-pain-100631188","NCT07497425","Neuroimmune Responses to Exercise in Chronic Back Pain","Neuroimmune Responses to Physical Exercise Training in Chronic Primary Low Back Pain","eCLBP","Inclusion Criteria-CLBP patients:\n\n* Have a diagnosis of chronic primary LBP, according to the criteria established by NIH Task Force on Research Standards for CLBP (Deyo et al., 2015). This will be determined by 1) the response to the National Institutes of Health minimum dataset for CLBP (NIH-md), including that LBP has been persistent for at least 3 months or recurrent for at least half of the days in the past 6 months, and 2) the results of a complete case history and physical examination (including functional tasks, quantitative sensory testing, and, if needed, neuro-orthopedic, palpation and range of motion assessments);\n* Report a CLBP intensity of at least 4 in a 0-10 numerical rating scale (0 = no pain, 10 = maximum possible pain).\n\nInclusion Criteria-Healthy controls:\n\n\\- Be over 18 years and under 75 years of age;\n\nExclusion Criteria-CLBP patients:\n\n* Present any red flags indicative of serious pathology comorbid or as the cause of CLBP (Finucane et al., 2020);\n* Have a CLBP phenotype characterized by predominant nociceptive (as in fracture, infection, malignancy, inflammatory or rheumatic spondyloarthropathy, cauda equina syndrome, confirmed by MRI when suspected) or neuropathic pain mechanisms, the latter assessed through score in the DN4 questionnaire (Nijs, et al., 2024);\n* Present chronic or acute pain of higher intensity or perceived disability in any other body site than the low back;\n* Medical history of diabetes, neurological or psychiatric disorder;\n* Presence of significant cardiorespiratory problems or any other potential contraindications to physical exercise as assessed through the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+);\n* Following a regular structured PE training program (\\>60 min\u002Fweek) at study's onset, and;\n* Presence of any contraindications to MRI examination (including any metallic implants or devices, being pregnant, and claustrophobia).\n\nExclusion criteria-Healthy controls:\n\n* Have symptoms or a diagnosis of any acute or chronic pain conditions;\n* Medical history of diabetes, neurological or psychiatric disorder;\n* Presence of significant cardiorespiratory problems or any other potential contraindications to physical exercise as assessed through the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+);\n* Following a regular structured PE training program (\\>60 min\u002Fweek) at study's onset, and;\n* Presence of any contraindications to MRI examination (including any metallic implants or devices, being pregnant, and claustrophobia).","75 Years",{"count":376,"type":23},216,[26],"The goal of this mechanistic clinical trial is to learn how physical exercise affects the body and brain in people with chronic low back pain. The study will examine whether a 12-week online exercise program changes these measures compared with a waitlist group. Researchers will also study immune activity and brain function in people with chronic low back pain and compare them with healthy participants. Participants will complete questionnaires, provide blood samples, and undergo brain imaging scans.",[29],[381,382,383,384,152,385],"mechanisms","immune system","inflammation","brain","exercise","2026-03-24",{"date":388,"type":39},"2026-03-27",{"date":390,"type":39},"2025-06-01",{"date":392,"type":23},"2029-06-30",{"name":394,"class":46},"McGill University",{"id":396,"slug":397,"hasResults":12,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":401,"eligibilityCriteria":402,"healthyVolunteers":12,"sex":19,"minAge":345,"maxAge":20,"enrollmentInfo":403,"targetDuration":4,"studyType":24,"phases":405,"briefSummary":406,"conditions":407,"keywords":408,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":47},"100629500","exercise-based-strategies-for-chronic-back-pain-100629500","NCT07475481","Exercise-Based Strategies for Chronic Back Pain","Innovative Exercise-Based Strategies for Managing Chronic Back Pain: A Multisystem Health Approach","BACK-FIT","Inclusion Criteria:\n\n* Chronic low back pain lasting more than 12 weeks, with current low back pain at screening\u002Fbaseline.\n* Resting blood pressure below 139\u002F89 mmHg.\n* Health status allowing participation in moderate-intensity resistance training and aerobic activity.\n* Physically active, but not professional athletes.\n* Non-smoker.\n* Able and willing to provide written informed consent and comply with study procedures\n\nExclusion Criteria:\n\n* Absolute or relative contraindications to resistance training or other clinically relevant cardiovascular contraindications.\n* Coronary artery disease, heart rhythm disorders, acute myocarditis, Marfan syndrome, or other cardiovascular conditions judged unsafe by the study physician.\n* History of myocardial infarction, cerebrovascular disease, peripheral vascular disease, or grade II-IV hypertension.\n* Type 1 or type 2 diabetes mellitus.\n* Severe obesity (BMI \\>= 40.0 kg\u002Fm2).\n* Infectious disease at screening (for example, COVID-19 or influenza).\n* Current treatment for chronic low back pain from another healthcare provider.\n* Prior spine surgery or lower-limb surgery.\n* Structural spinal deformity such as spondylolisthesis or spondylolysis.\n* Spinal fracture, inflammatory spinal disorder, or neurological signs of nerve root compromise, including decreased tendon reflexes, sensory loss, or motor deficits.\n* Dizziness during exercise.\n* Use of medications other than analgesics and non-steroidal anti-inflammatory drugs, unless specifically approved by the study physician.",{"count":404,"type":23},120,[26],"This randomized, controlled, five-arm, parallel-group trial will evaluate the effects of 8 weeks of supervised resistance training and developmental position-based exercise, with or without real-time non-invasive intra-abdominal pressure biofeedback, in adults aged 40 to 60 years with chronic low back pain. The trial will compare supervised gym-based agonist-antagonist paired set resistance training with OHMTRACK, supervised gym-based resistance training without OHMTRACK, supervised physiotherapy-based developmental exercise with OHMTRACK, home-based developmental exercise with OHMTRACK, and an active control condition. Primary outcomes will assess changes in pain and physical function after the intervention. Secondary outcomes will include neuromuscular coordination, postural stabilization, cardiovascular, respiratory, metabolic, behavioral, feasibility, and follow-up outcomes.",[62],[189,409,410,411,412,413,414,415],"resistance training","exercise therapy","dynamic neuromuscular stabilization","developmental positions","intra-abdominal pressure","rehabilitation","postural stabilization","2026-03-11",{"date":418,"type":39},"2026-03-16",{"date":420,"type":23},"2027-07-01",{"date":422,"type":23},"2030-03-31",{"name":424,"class":46},"Charles University, Czech Republic",{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":429,"acronym":4,"eligibilityCriteria":430,"healthyVolunteers":12,"sex":19,"minAge":431,"maxAge":346,"enrollmentInfo":432,"targetDuration":4,"studyType":24,"phases":434,"briefSummary":435,"conditions":436,"keywords":437,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":448},"100616320","clinical-research-on-the-comparative-effectiveness-and-safety-of-jhg002-therapy-for-chronic-low-back-pain-a-multicenter-randomized-controlled-trial-100616320","NCT07304076","Clinical Research on the Comparative Effectiveness and Safety of JHG002 Therapy for Chronic Low Back Pain: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 19 to 69 years at the time of signing the informed consent.\n* Individuals who have experienced low back pain for ≥6 months, presenting with either continuous or intermittent symptoms.\n* Participants with a Numeric Rating Scale (NRS) score ≥ 5 for low back pain at screening.\n* Individuals who fully understand the clinical trial procedures and voluntarily agree to participate by providing written informed consent.\n\nExclusion Criteria:\n\n* Patients diagnosed with serious underlying conditions that may cause low back pain, such as spinal metastasis of malignancy, acute vertebral fracture, or spinal dislocation.\n* Patients with progressive neurological deficits or those presenting with severe neurological symptoms.\n* Patients whose pain originates from non-spinal soft tissue disorders, including tumors, fibromyalgia, rheumatoid arthritis, or gout.\n* Individuals with other chronic medical conditions that may interfere with treatment response or interpretation of study outcomes, such as stroke, myocardial infarction, chronic kidney disease, diabetic neuropathy, dementia, or epilepsy.\n* Individuals currently taking corticosteroids, immunosuppressants, psychiatric medications, or any other drugs that may influence study results.\\*\n* Patients for whom pharmacopuncture is inappropriate or unsafe, including those with bleeding disorders or those receiving anticoagulant therapy.\n* Individuals who have taken analgesic medications such as NSAIDs or received pharmacopuncture treatment within the past 1 week.\n* Women of childbearing potential who are unwilling to use medically acceptable contraception (e.g., surgical sterilization, intrauterine device, condom or diaphragm use, injectable or implantable contraceptives) throughout the study period.\n* Pregnant or breastfeeding women.\n* Individuals with a history of hypersensitivity or allergic reactions to Hominis placenta pharmacopuncture (JHG002).\n* Patients with uncontrolled diabetes mellitus (fasting blood glucose ≥ 180 mg\u002FdL).\n* Individuals whose AST (GOT) or ALT (GPT) levels are ≥ 2 times the upper limit of the normal range at the study site.\n* Individuals whose serum creatinine levels are ≥ 2 times the upper limit of the normal range at the study site.\n* Patients suspected of having an underlying organic disease.\n* Patients with moderate systemic complications involving organs other than the heart, liver, or kidneys.\n* Patients with psychogenic disorders.\n* Individuals with an implanted cardiac pacemaker.\n* Patients with inflammation, infection, wounds, or other lesions at the planned pharmacopuncture sites that would prevent safe administration.\n* Patients within 3 months after lumbar spine surgery.\n* Individuals who have participated in another clinical trial within the past 1 month, or who plan to participate in another clinical trial-including follow-up periods-within 6 months from the screening date.\n* Any individual deemed unsuitable for participation in this study by the investigator.","19 Years",{"count":433,"type":23},96,[26],"A multicenter randomized controlled trial",[29],[189,438],"pharmacopuncture","2026-02-24",{"date":441,"type":39},"2026-02-25",{"date":443,"type":39},"2025-12-17",{"date":445,"type":23},"2029-11-28",{"name":447,"class":46},"Jaseng Medical Foundation",4,{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":455,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":19,"minAge":56,"maxAge":4,"enrollmentInfo":457,"targetDuration":4,"studyType":24,"phases":459,"briefSummary":460,"conditions":461,"keywords":462,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":474},"100610044","a-superiority-trial-of-radiofrequency-ablation-for-low-back-pain-100610044","NCT07222462","A Superiority Trial of Radiofrequency Ablation for Low Back Pain","ASTRAL: A Superiority Trial of Radiofrequency Ablation for Low Back Pain","ASTRAL","Inclusion Criteria:\n\n* Age ≥18 years\n* CLBP of duration ≥ 3 months. Low back pain is defined as occurring between the lower posterior margin of the rib cage and the horizontal gluteal fold.\n* Low back pain intensity numerical rating scale (NRS) ≥ 4 with one of the following prior to LRFA: 1) Current low back pain intensity, 2) Average pain over past 7 days, OR 3) Pain intensity without specification of recall period\n* Has had conservative treatments for CLBP (physical therapy, exercise therapy, spinal manipulation, massage, acupuncture, etc.)\n* Candidate for unilateral LRFA (L1-S1 joints; ≤3 levels); or bilateral LRFA (L1-S1 joints; ≤2 levels)\n* 'Positive responses' (≥80% improvement of CLBP pain intensity) to 2 sets of anesthetic-only MBBs (≤0.5cc of local anesthetic)\n* Able to read, speak, and understand English sufficient for informed consent purposes\n* Stated willingness to comply with all study processes and availability for the duration of the study, and provision of a signed and dated informed consent form\n\nExclusion Criteria:\n\n* CLBP attributed primarily to specific spine-related conditions (radiculopathy, lumbar spinal stenosis, spinal instability), 'red flag' conditions (infection \u002F malignancy \u002F fracture), and\u002For inflammatory arthritis (RA, SpA, etc.)\n* Prior LRFA\n* Prior lumbar facet joint (intra-articular or medial branch nerve) corticosteroid injections (past 6 months)\n* Surgery involving one or more of spinal levels where LRFA is to be performed, in the past 2 years\n* Lumbar fusion involving the spinal levels where LRFA is considered, at any time\n* Prior known severe lumbar central canal stenosis on MRI as defined by Lee (2011): obliteration of the cerebrospinal fluid (CSF), and marked compression of dural sac, and none of the cauda equina can be visually separated from each other. No new MRIs would be done specifically as part of the study processes.\n* Prior formal diagnosis of fibromyalgia by a rheumatologist (diagnosis by primary care physician or pain medicine specialist is not sufficient)\n* Unstable psychiatric or terminal medical conditions that would limit study participation and the likelihood of follow-up for 12 months post-randomization\n* Pregnancy, being a prisoner, or having a prior formal diagnosis of cognitive impairment by a neuropsychologist or neurologist, confirmed by health record documentation\n* Participant report of prior formal diagnosis of cognitive impairment by a neuropsychologist or neurologist can be obtained, but participant-reported cognitive impairment by a neuropsychologist or neurologist must be confirmed via health record documentation. No new evaluations for cognitive impairment would be done specifically as part of the study processes.\n* Contraindication to local anesthetic, corticosteroid, or any aspects of LRFA\n* Cannot reach MBB targets with 11.9cm needle\n* Major planned life events over the next 4 months that might interfere with study participation (e.g., major abdominal or chest surgery or extended vacation)",{"count":458,"type":23},300,[26],"The purpose of the ASTRAL Study is to evaluate the effectiveness of LRFA (Lumbar radiofrequency ablation) against a control procedure. The ASTRAL Study will enroll individuals with chronic low back pain (CLBP) and randomly assign them to one of three groups: lumbar radiofrequency ablation using conventional electrodes placed parallel to the medial branch nerves (LRFA-C), lumbar radiofrequency ablation using multi-tined electrodes placed perpendicular to the medial branch nerves (LRFA-M), or a simulated radiofrequency ablation procedure.",[29],[463,464],"lumbar radiofrequency ablation (LRFA)","corticosteroid injections","2026-02-05",{"date":467,"type":39},"2026-02-09",{"date":469,"type":39},"2026-02-04",{"date":471,"type":23},"2029-08",{"name":473,"class":46},"University of Washington",3,{"id":476,"slug":477,"hasResults":12,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":4,"eligibilityCriteria":481,"healthyVolunteers":12,"sex":19,"minAge":56,"maxAge":374,"enrollmentInfo":482,"targetDuration":4,"studyType":24,"phases":484,"briefSummary":485,"conditions":486,"keywords":489,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":4},"100619534","connective-tissue-dry-needling-for-low-back-pain-related-to-local-posterior-superior-iliac-spine-pain-100619534","NCT07345871","Connective Tissue Dry Needling for Low Back Pain Related to Local Posterior Superior Iliac Spine Pain","Investigating the Effectiveness of Connective Tissue Dry Needling Technique on Patients With Low Back Pain Caused by Local Pain at Superior Posterior Iliac Spine: a Single-blind, Randomized Controlled Trial","Inclusion criteria:\n\n1. Adults aged 18 to 75 years.\n2. Diagnosed with chronic mechanical low back pain localized at the posterior superior iliac spine region.\n3. Presence of point tenderness reproducible by palpation at the posterior superior iliac spine area.\n4. Pain duration of at least two weeks, indicating the non-acute stage of low back pain.\n5. Negative results in at least three out of five sacroiliac pain provocation tests (Distraction, Compression, Thigh Thrust, Sacral Thrust, Gaenslen).\n6. Pain intensity ≥ 3 on the Numeric Rating Scale at baseline.\n7. Ability to communicate and cooperate with the research team during intervention and follow-up.\n8. Access to WhatsApp or equivalent communication application for follow-up pain reporting at the 3-month stage.\n\nNon-inclusion criteria:\n\n1. Presence of lumbar radicular pain or referred pain to the lower limbs.\n2. History of lumbar spine trauma within the previous three months.\n3. Fear or intolerance of needling procedures.\n4. Current use of anticoagulant medication.\n5. Known lymphatic disorders, immunosuppressive diseases, or neurological conditions such as epilepsy or seizure disorders.\n6. Pregnancy or suspected pregnancy.\n\nExclusion criteria:\n\n1. Voluntary withdrawal of consent at any time during the study.\n2. Inability to tolerate the intervention or adverse reaction during treatment sessions.\n3. Occurrence of serious adverse events or complications (e.g., infection, bleeding).\n4. Non-compliance with treatment protocol or missing more than two sessions.\n5. Any intercurrent illness or therapy that could interfere with the study outcomes or safety assessment",{"count":483,"type":23},42,[26],"This single-blind randomized controlled trial will aim to determine the effectiveness of a connective tissue dry needling (CTDN) technique, in reducing pain and improving function in individuals with chronic mechanical low back pain associated with pain and tenderness at the posterior superior iliac spine (PSIS). Forty participants with local PSIS-related low back pain will be recruited and randomly assigned into two groups using the block balanced randomization method. The treatment group will receive CTDN targeting connective tissue trigger points around the PSIS in addition to a sacroiliac joint stabilization exercise program, while the control group will perform the same exercise program alone under the supervision of a physiotherapist. The intervention protocol will span two weeks, during which participants will attend three treatment sessions per week, for a total of six sessions. The primary outcome measurement will use the Visual Analog Scale (VAS) to assess pain intensity. The study will measure secondary outcomes through lumbar range of motion (ROM) in flexion and extension and pressure pain threshold (PPT), and Roland-Morris Disability Questionnaire (RMDQ) functional disability and Short Form-36 (SF-36) health-related quality of life. The researchers will assess all outcomes at three time points: baseline and after the first session, and the sixth session, while VAS will receive an additional assessment at the 3-month follow-up. The findings of this study are expected to provide evidence supporting CTDN as a safe, effective, and cost-efficient treatment option for PSIS-related mechanical low back pain.",[29,487,488],"Sacroiliac Joint Dysfunction","Mechanical Low Back Pain",[488,487,490,491,492],"Connective Tissue Disorders","Dry Needling","Fascia \u002F Fascial Manipulation","2026-01-18",{"date":495,"type":39},"2026-01-21",{"date":497,"type":23},"2026-04-10",{"date":499,"type":23},"2026-09-01",{"name":501,"class":46},"University of Social Welfare and Rehabilitation Science",{"id":503,"slug":504,"hasResults":12,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":4,"eligibilityCriteria":508,"healthyVolunteers":12,"sex":19,"minAge":56,"maxAge":144,"enrollmentInfo":509,"targetDuration":4,"studyType":24,"phases":510,"briefSummary":511,"conditions":512,"keywords":513,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":527,"locationsCount":529},"100592925","combining-brain-stimulation-and-physiotherapy-for-the-management-of-chronic-low-back-pain-100592925","NCT06999772","Combining Brain Stimulation and Physiotherapy for the Management of Chronic Low Back Pain","Combining Non-invasive Brain Stimulation and Physiotherapy to Improve the Management of Chronic Low Back Pain in Veterans","Inclusion Criteria:\n\n* Adults between 18 and 65 years old\n* Military Veterans with non-specific chronic low back pain (\\> 3 months, \\> 50% of the days in the last 6 months)\n* High level of psychosocial factors, scoring ≥4 on the Start Back Screening Tool\n* Functional limitations, scoring ≥ 15% on the Oswestry Disability Index (ODI)\n\nExclusion Criteria:\n\n* Non-musculoskeletal conditions causing low back pain (e.g., neoplasia, fracture)\n* Diagnosis of drug or alcohol abuse\n* Change of drug dosage in the last month for the treatment of pain or mental health\n* Presenting with any specific rTMS-related exclusion criteria such as previous seizure\u002Fconvulsion, cochlear implant, and pregnancy",{"count":433,"type":23},[26],"Chronic low back pain (CLBP) is a major health challenge in Canada, leading to substantial disability and socioeconomic burden, particularly among Veterans. In military Veterans, LBP is the most common chronic pain condition. Conventional interventions have limited effectiveness. The refractoriness to interventions suggests that specific CLBP mechanisms may be missed by current treatments, prompting a shift towards psychologically informed approaches which aim to address emotional and cognitive factors alongside biomedical aspects. The integration of these concepts into physiotherapy is called psychologically informed physiotherapy (PiP). Despite promising results of PiP from randomized controlled trials, residual pain and disability often persist in Veterans. Non-invasive brain stimulation, such as repetitive transcranial magnetic stimulation (rTMS), may enhance the effectiveness of PiP by modulating cognition, emotion, and pain. This proposal seeks to determine whether non-invasive brain stimulation can enhance the effects of PiP.",[62],[514,515,152,516,517,518,519],"Non-invasive brain stimulation","comorbid psychological risk factors","repetitive transcranial magnetic stimulation","physiotherapy","pyschologically-informed","veterans","2026-01-16",{"date":522,"type":39},"2026-01-20",{"date":524,"type":39},"2025-06-11",{"date":526,"type":23},"2027-06-01",{"name":528,"class":46},"Laval University",2,{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":4,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":537,"minAge":56,"maxAge":144,"enrollmentInfo":538,"targetDuration":4,"studyType":24,"phases":540,"briefSummary":541,"conditions":542,"keywords":547,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":558,"locationsCount":47},"100619994","effects-of-pemm-in-chronic-low-back-pain-women-with-urinary-incontinence-100619994","NCT07351851","Effects of PEMM in Chronic Low Back Pain Women With Urinary Incontinence","Effects of PEMM in Chronic Low Back Pain Women With Urinary Incontinence A Randomised Controlled Trial","Inclusion Criteria:\n\n* Age group of 18 - 65 years\n* Has child\u002Fchildren \\\u003C5 parity\n* CLBP patients with UI referred for physiotherapy for CLBP\n* Patient with low back pain for more than 3 months\n* NRS more than 5\u002F10\n* Patient with complain of urinary incontinence since past 3 months or more\n\nExclusion Criteria:\n\n* Chronic Low Back Pain with red flags\n* Not able to read and write in English \u002FArabic\n* Pregnant ladies and post partum 1 year\n* UTI, Pelvic floor Surgery\n* Any systemic condition of renal and cardiac\n* Patient with active carcinoma or any inflammatory disease","FEMALE",{"count":539,"type":23},200,[26],"Urinary incontinence (UI), Chronic low back pain (CLBP) in women are prevalent and often coexist. Multiple conditions when coexist, it leads to reduced Quality of life in turn causing physical and mental impairment. Musculoskeletal structures and fascial restrictions is one of the attribute to the coexistence of urinary incontinence and chronic back pain in women. External myofascial mobilization (EMM) with core exercises have been proven beneficial for conditions in males that is caused by musculoskeletal and fascial structures. However there are limited research which proves the effect of EMM in conditions involving musculoskeletal and fascial structures . Therefore, the aim of the study is to find the effect of MFTs in reducing the disability in women with CLBP and UI PRIMARY OBJECTIVE To evaluate the effectiveness of PEMM treatment in reducing disability, pain and improving mental health in women with CLBP and UI Study design : Simple randomization Sampling method: Simple Random sampling Random numbers will be generated in Excel, then random numbers will be presented in a concealed envelope for the participants to choose Sample Size : 130 (Experimental 65, Control 65) Sample size was determined using expected effect size i.e., mean change in the primary outcome variable disability index reported in the recent research study . With effect size (change in the disability index score) 3.5 and standard deviation of the change in the outcome 6.45, statistical power 80% and level of significance 5%, the required sample size would be n=55 participants in each group. However, to accounts for multiple secondary outcome measures, possible dropouts and non-response it would be good to increase an additional 20% in calculated sample size i.e., a total of 130 participants (65 participants in each group) will be included in this study.\n\nThe following sample size equation was used to determine adequate sample size:n = \\[2 (Z?\u002F2 + Z?)2 \\* ?2\\] \u002F (m1-m2)2 Where Z? and Z? are the values standard normal variate e.g., at 5% level of significance Z?\u002F2 = 1.96, and with 80% power the value of Z?= 0.84; ? is the polled Standard deviation and m1 and m2 are the mean outcome values s in group 1 and group 2 respectively.\n\nBlinding:\n\nSingle blinding: patient will be blinded to the group allocation. The assessor is blinded to the treatment\n\nMaterial and tools :\n\nTheragun - Theragun Elite, 20 V, Myofascial tools - foam roll, foam ball, Questionnaires - SF 3642,43,44, Oswestry Low back pain questionnaire (ODI)45 and The International Consultation on Incontinence Questionnaire Urinary Incontinence Short Form (ICIQ-UI-SF)46 PROCEDURE In the course of the study the total number of patients referred to physiotherapy department with LBP will be interviewed to identify patients with or without UI having LBP. The data obtained from this will be recoded as prevalence in results. The documents of the patients having LBP with UI will be reviewed to check who fulfills the inclusion criteria. All who meets the inclusion criteria will be approached face to face with the aim of the study. Informed consent form will be given to patients who are volunteering to participate in the study. The data of the participants who do not wish to participate in the study will also be recorded.\n\nThe participants who have consented to participate in the study will be then assessed. Since the participants has UI she will be directed to a Urologist for an assessment. After urologist assessment, patients will be randomly allocated to experimental and control groups. Random allocation will be administered by the random numbers generated and will be presented in a concealed envelope for the participants to choose. 1st week, the demographic data and Outcome measure of pain, SF36, ODI, ICIQ-UI-SF will be recorded (1st time) on the day of assessment. The outcome measures will be printed on paper and will be given to the patients to fill up with a pen, all questionnaires are self reported outcome measures. Treatment will commence a week after, where experimental group will undergo PEMM therapy with strengthening for 6 weeks duration and the control group will have conventional symptomatic pain treatment with strengthening (2nd to 7th week). Treatment will be given for 6 weeks (1 sessions in a week). The treatment day may vary any day between 4th and 7th day post one session. After 6 sessions of treatment, patient will be advised HEP (Home exercise program) to continue at home. Reassessment will be done on the 8th week where the outcome measures of pain, SF36, ODI, ICIQ-UI-SF will be recorded. Participants will be educated and advised regarding HEP. Exercises will be taught to the patient by explanation, demonstration, teach-back method, and printed sheet of exercise. Compliance to HEP will be recorded before final Outcome measure",[62,543,544,545,546],"Urinary Incontinence (UI)","Pelvic External Myofascial Mobilisation","Myofascial Techniques","Pelvic Pain",[189,548,549,550,551],"urinary incontinence","myofascial mobilisation","PEMM","female pelvic pain","2026-01-11",{"date":522,"type":39},{"date":555,"type":39},"2025-09-29",{"date":557,"type":23},"2027-12",{"name":559,"class":165},"Hamad Medical Corporation",{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":565,"acronym":4,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":19,"minAge":567,"maxAge":568,"enrollmentInfo":569,"targetDuration":4,"studyType":24,"phases":570,"briefSummary":571,"conditions":572,"keywords":573,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":578,"completionDateStruct":580,"leadSponsor":582,"locationsCount":47},"100619594","percussive-massage-therapy-using-heat-attachment-in-chronic-low-back-pain-100619594","NCT07346651","Percussive Massage Therapy Using Heat Attachment in Chronic Low Back Pain","The Effect of Percussive Massage Therapy Using a Heat Therapy Attachment on Pain and Disability in Patients With Chronic Low Back Pain","Inclusion Criteria:\n\n* Age 25 to 55 years.\n* Diagnosis of chronic low back pain confirmed by a physician (pain localized to the lumbar region, above the inferior gluteal folds and below the costal margin) with a duration of ≥ 3 months.\n* Baseline pain intensity of 30-80 mm on the Visual Analog Scale (3 cm ≤ VAS ≤ 8 cm).\n\nExclusion Criteria:\n\n* History of, or planned, surgery involving the low back or abdominal region.\n* Malignancy, vertebral fracture, or other serious spinal pathology.\n* Spinal injection or intervention within the past 3 months (e.g., epidural injection, facet joint steroid injection, neuroplasty).\n* Long-term use of analgesic or corticosteroid medications that may affect musculoskeletal symptoms.\n* Diagnosis of radiculopathy or neuropathy (with or without spinal canal stenosis).\n* Cognitive impairment that would preclude providing informed consent.\n* Significant structural spinal deformity (e.g., spondylolisthesis, congenital spinal deformities).\n* Progressive neurological disorder affecting the lower limbs\u002Fspine or inflammatory spinal disease (e.g., axial spondyloarthritis), or cardiovascular instability.\n* Pregnancy.\n* Medical conditions contraindicating exercise participation","25 Years","55 Years",{"count":206,"type":23},[26],"Low back pain is a global problem that currently affects many people's participation in daily activities, and its prevalence has been increasing over the years. Exercise is among the most effective treatment approaches for reducing and preventing pain and disability related to low back pain. To enhance the effects of exercise, various adjunctive methods may be needed. Local vibration applications delivered through mechanical devices are offer practical and time-efficient application, which may reduce the physiotherapist's manual workload, while also providing potential benefits for patients with musculoskeletal pain. Therefore, the aim of this study is to investigate the effects of Percussive Massage Therapy (PMT) applied using a heat-therapy attachment on pain, disability, spinal mobility, health-related quality of life, kinesiophobia, and patient satisfaction in individuals with chronic low back pain.\n\nPatients with chronic low back pain who meet the inclusion criteria will be randomly assigned to either the PMT group or the Control group (CG). All participants will receive a conventional rehabilitation program consisting of supervised exercise training and transcutaneous electrical nerve stimulation (TENS) for 2 weeks, 5 days per week, for approximately 45 to 60 minutes per day. The CG will receive only this conventional rehabilitation program. In addition, participants in the PMT group will receive PMT immediately after each conventional rehabilitation session, consisting of an 8-minute application (4 minutes per side) over the paravertebral muscles using a percussive massage therapy device.\n\nOutcome measures will be assessed at baseline and post-treatment (end of week 2). Pain intensity will be evaluated using the Visual Analog Scale (VAS); disability using the Oswestry Disability Index (ODI); spinal flexibility using the finger-to-floor distance test; health-related quality of life using the Short Form-36v2 (SF-36v2); and kinesiophobia using the Tampa Scale for Kinesiophobia (TSK). Treatment satisfaction will be assessed post-treatment using the Global Perceived Effect Scale (GPE), and all data will be recorded on a data collection form.",[29],[328,574,575,385],"percussive massage therapy","vibration","2026-01-08",{"date":520,"type":39},{"date":579,"type":23},"2026-01-12",{"date":581,"type":23},"2026-08",{"name":583,"class":46},"Fenerbahce University",{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":4,"eligibilityCriteria":590,"healthyVolunteers":18,"sex":19,"minAge":56,"maxAge":144,"enrollmentInfo":591,"targetDuration":4,"studyType":24,"phases":593,"briefSummary":595,"conditions":596,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":599,"lastUpdatePostDateStruct":600,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":606,"locationsCount":47},"100616496","phase-2-psilocybin-assisted-physical-therapy-in-chronic-low-back-pain-100616496","NCT07306364","Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain","Psilocybin in Chronic Low Back Pain: An Integrative Study of Lab-Based Mechanisms and Real-World Physical Therapy Outcomes","Inclusion Criteria:\n\n* 1\\. Ability to provide informed consent in English.\n* 2\\. Provision of signed and dated informed consent form.\n* 3\\. Stated willingness to comply with all study procedures and availability for the duration of the study.\n* 4\\. Male and female participants aged 18-65 years.\n* 5\\. CLBP, uniformly defined as high-impact or bothersome non-cancer low back pain lasting ≥ three months that occurs most days and limits life or work activities.\n* 6\\. At least moderate pain-related disability as measured by a total score on the ODI ≥ 15.\n* 7\\. For women of childbearing potential, must have a negative urine pregnancy test at screening and immediately before dose administration.\n\n  * Negative urine pregnancy test at screening and immediately before dose administration.\n  * Use of one highly effective contraception (e.g., IUD, barrier method) for ≥ 1 month prior to screening.\n* 8\\. Participants are required to commit to employing dual contraceptive methods throughout the study and to abstain from sperm or egg donation during the study period and for 28 days following the final drug dose for ova, and for 90 days following the final drug dose for sperm. Dual contraceptive methods encompass the use of a barrier contraceptive, such as condoms, coupled with another effective method capable of preventing pregnancy, such as oral or parenteral contraceptives, intrauterine devices, spermicide, and the like.\n* 9\\. Resting blood pressure ≤ 140\u002F90 mmHg (average of three screenings) and resting heart rate 60-100 bpm.\n* 10\\. Normal screening EKG: QTcF \\\u003C 450 ms; no clinically significant arrhythmias, ischemia, or bundle branch block.\n* 11\\. Hepatic and renal function within acceptable limits: AST\u002FALT ≤ 2× ULN; bilirubin ≤ 1.5× ULN; eGFR ≥ 50 mL\u002Fmin\u002F1.73 m².\n* 12\\. Ability to safely ingest oral capsules for the dosing visit.\n* 13\\. Safe transportation plan after the dosing session (e.g., designated driver).\n* 14\\. Signed medical release permitting the study team to communicate with outside providers for medication\u002Ftherapy history or crisis management.\n* 15\\. Designation of an adult emergency contact (relative, spouse, close friend) willing to monitor for mood\u002Fbehavior changes post-dose and provide transportation if needed.\n* 16\\. Agreement to attend preparatory and integration sessions, follow-up visits, and to respond to telephone\u002Femail contacts.\n\nExclusion Criteria:\n\n* 1\\. Hallucinogen Use Disorder or Hallucinogen Persisting Perceptual Disorder.\n* 2\\. Personal or family history of schizophrenia, schizoaffective disorder, bipolar disorder, or major depressive disorder with psychotic features; any history of substance-induced psychosis or current psychotic symptoms at Screening per the Brief Psychiatric Rating Scale.\n* 3\\. Active suicidal ideation or behavior in the past 3 months, as indicated on the C-SSRS.\n* 4\\. Lifetime use of classic psychedelics (5-HT2A agonists) within the preceding 12 months, or unwillingness to abstain from their use for up to 4 weeks post-dose.\n* 5\\. Current moderate or severe depression, as indicated by a score of ≥ 3 on the depression subscale (items 1 and 2) of the Patient Health Questionnaire-4 (PHQ-4).\n* 6\\. Total score on the ODI ≥ 35, indicating an individual is \"completely disabled.\"\n* 7\\. Meeting DSM-5 criteria for alcohol or substance use disorders (other than tobacco use disorder) within the last year; use of THC-containing products \\> 2×\u002Fweek over the past 30 days or unwillingness to abstain for at least 1 week pre-dose through 4 weeks post-dose. Abstinence will be confirmed via point-of-care urine 11-nor-9-carboxy-THC testing with a cut-off ≤ 50 ng\u002FmL.\n* 8\\. Clinically significant medical disorders (e.g., moderate-to-severe hepatic impairment \\[Child-Pugh B\u002FC\\], AST\u002FALT \\> 2× ULN, bilirubin \\> 1.5× ULN, eGFR \\\u003C 50 mL\u002Fmin\u002F1.73 m², diabetes, uncontrolled thyroid disease).\n* 9\\. Neurological conditions altering nociceptive response (e.g., stroke, neuropathy) or history of seizure\u002Fhead injury with \\> 30 minutes loss of consciousness.\n* 10\\. Contraindications to nociceptive testing (e.g., untreated hypertension \\> 140\u002F90 mmHg).\n* 11\\. Current use of serotonergic medications (e.g., SSRIs, SNRIs, TCAs).\n* 12\\. Current regular use of medications affecting pain (e.g., opioids, gabapentinoids, cyclobenzaprine).\n* 13\\. Current regular use of inhibitors of UGT1A9, UGT1A10, MAO and aldehyde or alcohol dehydrogenase.\n* 14\\. Major neurocognitive disorders (e.g., dementia) or any cognitive deficit impairing consent\u002Fparticipation.\n* 15\\. Abnormal EKG findings (e.g., ischemia, infarct patterns, bundle branch block, atrial fibrillation, QTcF ≥ 450 ms).\n* 16\\. Resting QTcF prolongation or other torsades de pointes risk factors (uncontrolled electrolyte disturbances, family history of sudden death, torsadogenic medications).\n* 17\\. Any other condition that, in the investigator's judgment, would compromise safety or ability to complete the study.\n* 18\\. Known or suspected cardiovascular disease, including but not limited to atrial fibrillation, coronary artery disease, history of myocardial infarction, structural heart disease, congestive heart failure, or uncontrolled hypertension.",{"count":592,"type":23},45,[594],"PHASE2","The purpose of this research study is to investigate whether a single administration of psilocybin can improve interoceptive awareness (awareness of bodily sensations) in individuals with chronic low back pain undergoing physical therapy, and whether these improvements are linked to pain relief and better physical therapy outcomes.",[29,597,598],"Physical Therapy","Psilocybin","2025-12-24",{"date":601,"type":39},"2025-12-29",{"date":603,"type":23},"2026-06",{"date":605,"type":23},"2029-06",{"name":607,"class":46},"Yale University",{"id":609,"slug":610,"hasResults":12,"nctId":611,"briefTitle":612,"officialTitle":613,"acronym":4,"eligibilityCriteria":614,"healthyVolunteers":12,"sex":19,"minAge":615,"maxAge":346,"enrollmentInfo":616,"targetDuration":4,"studyType":24,"phases":618,"briefSummary":619,"conditions":620,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":622,"lastUpdatePostDateStruct":623,"startDateStruct":624,"completionDateStruct":626,"leadSponsor":627,"locationsCount":47},"100603178","treatment-validation-for-myofascial-pain-100603178","NCT07133139","Treatment Validation for Myofascial Pain","Treatment Validation of an Ultrasound Imaging Biomarker for Myofascial Pain","Inclusion Criteria:\n\n* Ages 20-70;\n* Predominantly axial LBP (meeting NIH definition of cLBP with daily pain for at least 3 months) with a MP component as determined by the standardized examination for MP;\n* Average pain score of \\> 3\u002F10, with low back pain being the primary pain site;\n* CLBP meeting Quebec Task Force Classification System categories I-III (from axial pain only to pain radiating beyond the knee without neurological signs). Constant radicular pain associated with sensory loss is likely a confounder to dry needling treatment success;\n* NO HISTORY of receiving dry needling, to improve the effectiveness of the blind;\n* Demonstration of healthcare seeking at some point for LBP.\n\nExclusion Criteria:\n\n* Back surgery within the past six months;\n* Active workers' compensation or litigation claims, since these patients are more likely to have exaggerated pain behavior;\n* New pain treatments within 2 weeks of enrollment;\n* Any clinically unstable systemic illness or condition that is judged to interfere with the trial;\n* Non-ambulatory status;\n* Not able to complete the questionnaire\n* Currently pregnant or have intentions to become pregnant during the study.","20 Years",{"count":617,"type":23},80,[26],"The goal of this clinical trial is to see if a body test called the NUN biomarker can track changes in chronic low back pain after dry needling and predict who will feel better. This study is for adults with chronic low back pain from muscle pain (Myofacial Pain).\n\nThe main questions are:\n\n* Does the biomarker drop when pain improves?\n* Can it predict who benefits most?\n* Do higher starting levels mean better results with real dry needling?\n\nInvestigators will compare real and fake (sham) dry needling using ultrasound, muscle pressure tests, and pain reports before and after treatment.",[62,621],"Myofacial Pain","2025-12-23",{"date":599,"type":39},{"date":625,"type":39},"2025-10-06",{"date":219,"type":23},{"name":628,"class":46},"Ajay Wasan, MD, Msc",{"id":630,"slug":631,"hasResults":12,"nctId":632,"briefTitle":633,"officialTitle":634,"acronym":635,"eligibilityCriteria":636,"healthyVolunteers":12,"sex":19,"minAge":56,"maxAge":4,"enrollmentInfo":637,"targetDuration":4,"studyType":24,"phases":638,"briefSummary":639,"conditions":640,"keywords":642,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":649,"lastUpdatePostDateStruct":650,"startDateStruct":651,"completionDateStruct":653,"leadSponsor":655,"locationsCount":47},"100615925","phase-2-resilience-enhancement-following-sleep-treatment-100615925","NCT07298941","Resilience Enhancement Following Sleep Treatment","An Adaptive Intervention to Improve Pain Outcomes Following Cognitive Behavioral Therapy for Insomnia in Patients With Comorbid Chronic Low Back Pain and Insomnia","REST","Inclusion Criteria:\n\n(1) age \\>=18 years; (2) report low back pain as ongoing problem \\>= 3 months and any pain on at least half of the days over the past 6 months (consistent with NIH Consensus Recommendations, other chronic pain problems can be present, but cLBP must be reported as primary); (3) average pain intensity \\>= 4 over past 7 days on a 0-10 numerical rating scale; (4) sleep-onset insomnia and\u002For sleep maintenance insomnia and\u002For late insomnia (\\>30 minutes of WASO or SOL or waking \\>30 minutes before desired time for at least 3 nights\u002Fweek) with presence of insomnia symptoms for \\>= 6 months, and the sleep disturbance (or associated daytime fatigue) must cause significant distress or impairment in social, occupational, or other areas of functioning to be consistent with DSM 5 criteria (evaluated by phone interview).\n\nExclusion Criteria:\n\n(1) currently receiving behavioral treatment for insomnia; (2) currently engaging in formal or informal meditation practice on a regular (e.g., weekly) basis; (3) unstable medication use for sleep, pain, or other indication (e.g., changed within the past 3 months); (4) irregular sleep schedules dictated by shift work (i.e., usual bedtimes outside 8:00 p.m.-2:00 a.m. or arising time outside 4:00 a.m.-10:00 a.m.); (4) mental health condition deemed to interfere with study procedures or put the participant at undue risk via semi-structured interview (e.g., screen positive for psychotic disorder) or other untreated sleep disorders (e.g., obstructive sleep apnea, restless legs syndrome) as evaluated by our semi-structured interview based on the Diagnostic Interview for Insomnia (DII); (5) do not have regular internet access; (6) cannot read and speak English (interventions only available in English); and (7) severe cognitive impairment (i.e., score =9 on the Telephone-Assessed Mental State); (8) currently pregnant; 9) unable or unwilling to comply with study protocols, or otherwise determined by the PI to be able to safely participate in the study.",{"count":458,"type":23},[594],"The primary objective of this study is to evaluate the efficacy of an adaptive intervention targeting both insomnia and positive affect in improving pain outcomes for adults with chronic low back pain (cLBP) and comorbid insomnia. Specifically, the study tests whether augmenting a cognitive behavioral therapy for insomnia (CBTi) program with a meditation intervention (Savoring Meditation) or a Pain Education intervention will result in greater reductions in pain intensity.\n\nSecondary objectives include evaluating improvements in insomnia severity, positive and negative affect, and overall quality of life.",[29,641],"Insomnia",[189,643,644,645,646,647,648],"insomnia","cognitive-behavioral therapy for insomnia","meditation","savoring","pain","internet intervention","2025-12-19",{"date":622,"type":39},{"date":652,"type":39},"2025-12-16",{"date":654,"type":23},"2030-04-30",{"name":656,"class":46},"University of Virginia",{"id":658,"slug":659,"hasResults":12,"nctId":660,"briefTitle":661,"officialTitle":662,"acronym":663,"eligibilityCriteria":664,"healthyVolunteers":18,"sex":19,"minAge":56,"maxAge":20,"enrollmentInfo":665,"targetDuration":4,"studyType":666,"phases":4,"briefSummary":667,"conditions":668,"keywords":671,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":689,"lastUpdatePostDateStruct":690,"startDateStruct":692,"completionDateStruct":694,"leadSponsor":695,"locationsCount":47},"100590931","studying-the-neurobiological-mechanisms-of-non-specific-chronic-low-back-pain-and-chronic-insomnia-a-four-group-cross-sectional-study-100590931","NCT06973837","Studying the Neurobiological Mechanisms of Non-specific Chronic Low Back Pain and Chronic Insomnia: a Four-group Cross-sectional Study","Unravelling the Neurobiological Mechanisms Underlying the Bidirectional Relationship Between Chronic Sleep Disturbances and Pain Sensitivity in People With Non-specific Chronic Low Back Pain and Chronic Insomnia","SY-NAPS-CS","General inclusion criteria (all groups):\n\n* 18-60 years old.\n* Ability to speak and understand the Dutch Language.\n* Body mass index \\\u003C30.\n* No smoking or nicotine use.\n* Low caffeine use (≤3 cups of coffee\u002Fday, ≤1 energy drink\u002Fday).\n* Low alcohol use (≤9 alcoholic units\u002Fweek).\n* No use of neuro- and\u002For psychopharmacological treatments and\u002For immunosuppressive agents (including NSAIDs) with a suspected influence on neuroinflammation unless terminated within a sufficient time frame before the start of the study, or unless falling under the Pharmacological exceptions criteria (see below).\n* Willing to (try to) adhere to the acute pre-test restrictions, including refraining from analgesics (unless stable use), caffeine, alcohol, and\u002For strenuous physical activity (\\>3 METs) in the 24 hours preceding the main test day.\n\nGeneral exclusion criteria (all groups):\n\n* Shift worker.\n* Use of blood thinners.\n* (History of) Substance dependence\u002Fabuse.\n* Chronic pain conditions (≥3 months) other than chronic low back pain.\n* Severe intrinsic sleep disorders (assessed during a one-night, laboratory-based polysomnography).\n* Restless leg syndrome\n* Central or peripheral neurological disorder\u002Fcondition (e.g., epilepsy, multiple sclerosis, peripheral neuropathy).\n* History of spinal surgery.\n* Major medical (e.g., cardiac disease, cancer) and\u002For psychiatric disorder\u002Fdisease (e.g., major depressive disorder, bipolar disorder).\n* Claustrophobia.\n* Contraindications for magnetic resonance imaging (e.g., metal\u002Fcochlear implants, pacemaker).\n* Pregnancy or being \\\u003C12 months post-natal.\n\nPharmacological exceptions criteria:\n\n\\- Participants with chronic low back pain and\u002For (comorbid) insomnia will be allowed to be on a stable low dose of weak pain and\u002For sleep agents (e.g., Tramadol, Zolpidem) if medically prescribed specifically for their low back pain and\u002For insomnia, and if approved by the national medicine register of Belgium (FAMHP, Federal Agency for Medicine and Health Products). These participants will also be allowed stable and\u002For occasional use of low-to-moderate doses of over-the-counter medications for pain and\u002For sleep that are suspected to have no or minimal impact on neuroinflammation (e.g., paracetamol, melatonin). Habitual use of medications according to the above-stated criteria should be maintained across the entire study period, with the only exception being analgesics taken on an occasional basis. Specifically, because of the extensive battery of pain tests that will be utilized in the study, all analgesics that are only taken occasionally should be refrained from during the 24 hours preceding the main test day (pre-test instructions).\n\nSpecific inclusion criteria for \"pain-free\" groups:\n\n* Currently pain free, defined as having no pain that affects daily living\u002Ffunctioning and\u002For which has led to a consultation with a healthcare practitioner.\n* No episode of low back pain that interfered with daily functioning\u002Fliving and\u002For which led to a consultation with a healthcare practitioner within 12 months from the time of inclusion.\n* No history of chronic low back pain.\n\nSpecific inclusion criteria for \"chronic low back pain\" groups:\n\n* Low back pain reported on most days (≥50%), every week, for more than 3 months.\n* Low back pain-related emotional disress OR functional disability rated as ≥3 out of 10.\n\nSpecific inclusion criteria for \"good sleeper\" groups:\n\n* Stable sleep phase within 10 PM and 10 AM (assessed using the Pittsburgh Sleep Quality Index).\n* Average habitual total sleep time between 7 and 9 hours (assessed using the Pittsburgh Sleep Quality Index).\n* A Pittsburgh Sleep Quality Index ≤5.\n* An Insomnia Severity Index ≤7.\n* An Epworth Sleepiness Scale ≤10.\n* Sleep efficiency ≥85% during a one-night, laboratory-based polysomnography screening.\n* No episode of sleep disturbances that interfered with daily functioning\u002Fliving and\u002For which led to a consultation with a healthcare practitioner within the preceding 12 months from the time of inclusion.\n* No history of chronic insomnia.\n\nSpecific inclusion criteria for \"chronic insomnia\" groups:\n\n* Chronic insomnia according to the ICSD-3-TR criteria (assessed using an ICSD-3-TR-adapted version of the Pittsburgh Sleep Quality Index).\n* An Insomnia Severity Index ≥15.",{"count":617,"type":23},"OBSERVATIONAL","This study is a part of a larger project aiming to evaluate the neurobiological mechanisms underlying the relationship between sleep and pain in people with non-specific chronic low back pain. Specifically, this study aims to evaluate the neurobiological mechanisms underlying the relationship between chronic sleep disturbances and pain sensitivity in people with non-specific chronic low back pain and chronic insomnia.",[29,669,670],"Chronic Insomnia","Neuroinflammation",[672,673,674,675,641,676,677,678,679,680,681,682,683,684,685,686,687,688],"Pain","Chronic pain","Chronic low back pain","Sleep","Chronic insomnia","Magnetic resonance imaging","Functional magnetic resonance imaging","Magnetic resonance spectroscopy","Diffusion weighted imaging","Quantitative sensory testing","Temporal summation","Conditioned pain modulation","Experience sampling method","Ecological momentary assessment","Microbiota","Gut-Brain axis","Short-chain fatty acids","2025-12-06",{"date":691,"type":39},"2025-12-15",{"date":693,"type":39},"2025-10-03",{"date":73,"type":23},{"name":696,"class":46},"Vrije Universiteit Brussel",{"id":698,"slug":699,"hasResults":12,"nctId":700,"briefTitle":701,"officialTitle":702,"acronym":703,"eligibilityCriteria":704,"healthyVolunteers":12,"sex":19,"minAge":56,"maxAge":144,"enrollmentInfo":705,"targetDuration":4,"studyType":24,"phases":706,"briefSummary":707,"conditions":708,"keywords":709,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":713,"lastUpdatePostDateStruct":714,"startDateStruct":716,"completionDateStruct":718,"leadSponsor":720,"locationsCount":529},"100584404","comparison-of-the-immediate-effect-of-passive-vs-passive-active-hamstring-stretching-on-flexibility-in-patients-with-chronic-low-back-pain-100584404","NCT06888895","Comparison of the Immediate Effect of Passive vs. Passive-Active Hamstring Stretching on Flexibility in Patients With Chronic Low Back Pain","Comparison of the Immediate Effect of Passive vs. Passive-Active Hamstring Stretching on Flexibility in Patients With Chronic Low Back Pain: Protocol for a Randomized Controlled Trial: EFIM2","EFIM2","Inclusion Criteria:\n\n* Male or female patients aged between 18 and 65 years\n* Suffering from low-back pain for at least 3 months\n* Presenting with hamstring flexibility deficit (Straight Leg Raise \\\u003C85°, Fingertip-to-Floor distance \\>5 cm)\n\nExclusion Criteria:\n\n* Patients with radicular pain\n* Disc inflammation (MODIC Type 1)\n* Other relevant pathologies (neurological, cardiovascular, respiratory, or oncological diseases)\n* Significant surgical history (e.g., lumbar arthrodesis, knee or hip arthroplasty)\n* Pregnancy or breastfeeding\n* Patients under protective legal measures",{"count":311,"type":23},[26],"The goal of this clinical trial is to determine whether a combination of passive and active hamstring stretching (PAS) is more effective than passive stretching alone (PS) in improving flexibility in patients with chronic low back pain (CLBP).\n\nThe main questions it aims to answer are:\n\nDoes PAS lead to greater improvements in active flexibility compared to PS? Does PAS provide additional benefits in passive flexibility, hamstring stiffness, and pelvic tilt? Researchers will compare the PAS group and the PS group to see if combining passive and active stretching results in greater improvements in flexibility and movement control.\n\nParticipants will:\n\nPerform either PAS or PS stretching exercises as assigned. Undergo measurements of flexibility, hamstring stiffness, and pelvic tilt before and after the intervention.\n\nAnswer a question about their perceived change in flexibility following the intervention.\n\nThis study aims to improve rehabilitation strategies for people with CLBP, helping them achieve better movement and pain relief.",[29],[710,189,711,712],"hamstring","extensibility deficit","passive stretching","2025-11-24",{"date":715,"type":39},"2025-11-25",{"date":717,"type":39},"2025-09-30",{"date":719,"type":23},"2028-04",{"name":721,"class":46},"University Hospital, Clermont-Ferrand"]